A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors IMPAX Laboratories
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Aug 2017.
- 02 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.